Clinical Trial Update: A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis

View source ↗

Summary

A Canadian clinical trial evaluating the utility of treatment optimization recommendations in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: COMPLETED